These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3126345)

  • 1. [Biotechnical production of drugs with special reference to tissue-type plasminogen activator].
    Werner RG
    Klin Wochenschr; 1988; 66 Suppl 12():24-32. PubMed ID: 3126345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriate mammalian expression systems for biopharmaceuticals.
    Werner RG; Noé W; Kopp K; Schlüter M
    Arzneimittelforschung; 1998 Aug; 48(8):870-80. PubMed ID: 9748718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of shear stress on intrinsic CHO culture state and glycosylation of recombinant tissue-type plasminogen activator protein.
    Senger RS; Karim MN
    Biotechnol Prog; 2003; 19(4):1199-209. PubMed ID: 12892482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells.
    Hagège J; Delarue F; Peraldi MN; Sraer JD; Rondeau E
    Lab Invest; 1994 Dec; 71(6):828-37. PubMed ID: 7807964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology.
    Browne MJ; Dodd I; Carey JE; Chapman CG; Robinson JH
    Thromb Haemost; 1985 Aug; 54(2):422-4. PubMed ID: 3936214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recombinant DNA technology in thrombolytic therapy: tissue-type plasminogen activator].
    Mazza P
    Boll Chim Farm; 1991 Mar; 130(3):105-7. PubMed ID: 1909876
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene technology: chances for diagnosis and therapy.
    Werner RG
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):525-37. PubMed ID: 7885080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drugs produced by genetic techniques].
    Bicker U
    Verh Dtsch Ges Inn Med; 1990; 96():451-65. PubMed ID: 2128725
    [No Abstract]   [Full Text] [Related]  

  • 10. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts.
    Hayakawa Y; Tazawa S; Ishikawa T; Niiya K; Sakuragawa N
    Thromb Haemost; 1995 Aug; 74(2):704-10. PubMed ID: 8585010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upflow anaerobic sludge blanket reactor--a review.
    Bal AS; Dhagat NN
    Indian J Environ Health; 2001 Apr; 43(2):1-82. PubMed ID: 12397675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
    Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on rt-PA production by recombinant CHO cells immobilized with a porous microcarrier.
    Zhaolie C; Benchuan W; Hong L; Shichong L; Peitang H
    Chin J Biotechnol; 1999; 15(4):239-44. PubMed ID: 11037949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
    Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recombinant murine cell lines, transformed by various vectors based on bovine type 1 papillomavirus and expressing human tissue plasminogen activator. II. Analysis of cell lines, producing recombinant tissue plasminogen activator].
    Aleshkov SB; Ustav MB; Baev AA
    Mol Biol (Mosk); 1994; 28(3):619-25. PubMed ID: 8052253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of new thrombolytic substances].
    Zeymer U; Neuhaus KL
    Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
    Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
    Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of ammonium on growth, metabolism, and productivity of a continuous suspension Chinese hamster ovary cell culture.
    Hansen HA; Emborg C
    Biotechnol Prog; 1994; 10(1):121-4. PubMed ID: 7764523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tissue-type plasminogen activator story.
    Collen D; Lijnen HR
    Arterioscler Thromb Vasc Biol; 2009 Aug; 29(8):1151-5. PubMed ID: 19605778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.